The U.S. Court of Appeals for the Third Circuit is taking an interlocutory appeal on a question that it opened after declaring last June that GlaxoSmithKline is a corporate citizen of Delaware, not Pennsylvania.
Since that opinion, which effectively preserved GSK’s ability to remove to federal court cases filed against it in Pennsylvania state courts, district judges have been splitting on the issue of whether or not the pharmaceutical giant can re-remove cases to the district courts after those cases had been remanded to state court before the circuit court’s June decision.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
